Brenus Pharma, French Biotech, aims to become leader in immuno-oncology thanks to our innovative, unique, patented technology : 🟣 Stimulated Tumor Cell (STC) 🟣 Developing an allogeneic platform designed to generate first in class therapeutic antigen-based immunotherapies : 💡Technology highlights💡 ▪️ Targeting over 200 cancer-related antigens allowing to anticipate mutation of cancer cells and treatment resistances. ▪️ 1st Immunotherapy combining impactful technologies with proven efficacy in 1 product, addressing limits of current treatments. ▪️ A complete off-the shelf approach based on stimulated allogeneic cell lines : allowing cost, timing and supply control and ensuring treatment’s availability to a wide population. 🌐Science aspects backed by word class scientific leaders. 🌐First in human clinical study for the lead candidate STC-1010 (mCRC) planed for early 2024 ; with worldwide investigators. ✅CMC expert ✅ ▪️ FDA pre-IND and 2 SA with EU FAMHP (Belgium Agency) done ▪️ Manufacturing readiness ▪️ Efficient and scalable GMP manufacturing process ▪️ Product fully characterized